Renovaro Inc. announces funding approval for LUMINA, a platform detecting minimal residual disease in lung cancer using multi-omics and AI.
Quiver AI Summary
Renovaro Inc. announced that its subsidiary, RenovaroCube, along with partners Flomics Biotech, Uppsala University, and Oncodia, has received funding approval for the Lumina project from the Eurostars program to develop an advanced Minimal Residual Disease detection platform for lung cancer. This platform will utilize a multi-omics approach and artificial intelligence to improve recurrence risk prediction and treatment strategies for lung cancer patients, a group that sees over 5.7 million cases treated globally each year. The project aims to create a non-invasive liquid biopsy solution that accurately detects residual disease, leveraging the expertise of its collaborative partners to enhance early cancer detection and treatment personalization. Renovaro's CEO, David Weinstein, emphasized the potential impact of Lumina on lung cancer patient survival rates and the commitment to bringing this innovative diagnostic tool to market.
Potential Positives
- Renovaro Inc.'s subsidiary RenovaroCube received grant funding approval for the Lumina project, positioning the company as a leader in cancer diagnostics backed by significant Eurostars funding.
- The Lumina project aims to develop an advanced Minimal Residual Disease detection platform for lung cancer, which addresses a critical unmet need in cancer care, potentially transforming patient outcomes.
- The project involves collaboration with prestigious institutions such as Uppsala University, Oncodia AB, and Flomics Biotech, enhancing the credibility and expertise behind the technology.
- This initiative leverages AI-driven multi-omics biomarker technology, indicating Renovaro's commitment to innovative solutions in precision medicine and personalized cancer treatment.
Potential Negatives
- The press release includes a cautionary note about forward-looking statements, indicating potential risks and uncertainties regarding the success of the LUMINA project and Renovaro's other initiatives, which may raise concerns among investors about the company's future.
- While the grant funding approval for the LUMINA project is a positive development, lack of details about the specific amount or terms of the funding may leave stakeholders questioning the financial implications for Renovaro.
- The mention of the significant relapse rate of lung cancer patients (60%) may highlight the gravity of the challenge the company is attempting to address, possibly casting doubt on the feasibility of achieving their ambitious goals within the projected timelines.
FAQ
What is the LUMINA project for lung cancer detection?
The LUMINA project aims to develop a platform that detects minimal residual disease in lung cancer using AI and multi-omics biomarkers.
Who are the partners in the LUMINA project?
The LUMINA project partners include RenovaroCube, Flomics Biotech, Uppsala University, and Oncodia AB.
How does LUMINA improve lung cancer patient outcomes?
LUMINA enhances lung cancer treatment by providing accurate, non-invasive detection of disease recurrence, aiding in personalized treatment strategies.
What technology does LUMINA utilize for disease detection?
LUMINA utilizes liquid biopsies combined with multi-omics biomarker technology and AI-driven analysis for improved accuracy in detecting lung cancer.
How significant is the funding for the LUMINA project?
The LUMINA project received grant funding approval from Eurostars, part of Horizon Europe, to support its development and commercialization efforts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RENB Insider Trading Activity
$RENB insiders have traded $RENB stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $RENB stock by insiders over the last 6 months:
- ANDERSON WITTEKIND WILLIAM has traded it 13 times. They made 0 purchases and 13 sales, selling 423,180 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RENB Hedge Fund Activity
We have seen 29 institutional investors add shares of $RENB stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 293,631 shares (-100.0%) from their portfolio in Q2 2024
- NORTHERN TRUST CORP added 291,413 shares (+96.0%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 155,995 shares (-9.0%) from their portfolio in Q3 2024
- MAN GROUP PLC removed 107,897 shares (-100.0%) from their portfolio in Q2 2024
- CANTOR FITZGERALD, L. P. added 100,000 shares (+inf%) to their portfolio in Q3 2024
- MORGAN STANLEY removed 97,770 shares (-21.5%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 75,576 shares (+1.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI
LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) --
Renovaro Inc. (NASDAQ: RENB),
a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary
RenovaroCube (the ‘Cube’)
, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, received grant funding approval for the Lumina project from the Eurostars funding program after review by an independent expert panel.
Eurostars is part of the European Partnership on Innovative SMEs (Small and Medium-sized Enterprises). The partnership is co-funded by the European Union through Horizon Europe. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialization, with over €250M in expected public-private investment each year.
The Lumina project aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.
“This award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization,” said David Weinstein, Chief Executive Officer of Renovaro. “In partnership with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech, the Lumina project is focused on improving lung cancer patient survival. Over 5.7 million lung cancer cases are treated or monitored globally each year, and of all curatively treated lung cancer patients, 60% will relapse. Lumina represents a significant opportunity to address this critical issue, and we look forward to continuing work with our partners to bring this product to market.”
A High-Performance Platform for Better Outcomes
The objective of the LUMINA project is to develop a cutting-edge platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies combined with multi-omics biomarker technology, represent a revolutionary approach. The LUMINA project’s AI-powered platform capitalizes on this potential, aiming to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.
Collaborative Expertise
The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, leveraging the analysis of cell-free DNA and RNA to ensure the platform’s success.
About Renovaro
Renovaro
https://renovarogroup.com/
aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
About RenovaroCube
RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).
RenovaroCube’s AI platform is purpose-built to process and analyze
multi-omic molecular data
, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:
Sequence Processing:
Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
Biomarker Discovery:
Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
AI Factory:
Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
Precision Diagnostics:
Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Flomics Biotech, S.L.
Flomics
https://www.flomics.com/
is a fast-growing biotech company based in Barcelona, operating in the genomics and liquid biopsy space. Flomics’ objective is to develop a revolutionary diagnostic blood test based on Next-Generation Sequencing (NGS) of cell-free RNA, suitable for the early detection of different complex diseases, in particular cancer. Additionally, as CRO, Flomics also offers the following services: biomarker discovery (on tissue and biofluids), support on bioinformatic analysis and an intuitive web-based platform suitable for the analysis of NGS data (Stratus). The team at Flomics has a strong background in RNA and liquid biopsy, as well as advanced bioinformatics analysis methods.
About Uppsala Universitet
Uppsala University is the first university in the Nordic countries and a world-class research institution. The Department of Immunology, Genetics and Pathology is dedicated to advancing cancer diagnostics and treatment through the study of molecular changes associated with cancer. The research aims to harness measurable molecular information to improve diagnosis and therapy, with a strong focus on developing liquid biopsy-based diagnostic tests. A key initiative is the U-CAN project, which provides a unique biobank of high-quality clinical samples and data from cancer patients to support translational research. This effort, combined with cutting-edge molecular biology and clinical expertise, underscores the university's commitment to transforming cancer care.
About Oncodia AB
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. Oncodia is committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Their focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com
and
STarsh@Renovarogroup.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
